Cancer Epidemiology: Implications for Prevention, Early Detection, and Treatment

Cancer Epidemiology


Implications for Prevention, Early Detection, and Treatment




OVERVIEW


Cancer continues to be a significant public health problem in the United States and throughout the world. Each year the American Cancer Society (ACS) estimates the number of new cancer cases and deaths expected in the United States in the current year. This report is an epidemiologic report of cancer in the United States that provides insight into trends in cancer and its care. For example, in 2007 the ACS reported that the number of cancer deaths decreased for the second consecutive year in the United States (Jemal et al., 2007).


Epidemiology is defined as the study of how disease is distributed in a population, factors that influence its distribution in a population, and trends over time. Although it often receives little attention in formal educational programs, an understanding of epidemiology is critical to understanding the biology of a disease and its possible risk factors and ultimately to developing prevention and treatment strategies. The study of epidemiology encompasses not only the basis of disease but also the impact of treatment, screening, and preventive measures on the natural history of the disease.


Epidemiologists believe that illness, disease, or poor health are not necessarily random events. Some persons have risk factors that place them at risk for development of disease. Thus risk assessment is a significant component of epidemiology. General goals of epidemiology and commonly used epidemiologic terms are shown in the boxes below and on page 4.



TYPES OF EPIDEMIOLOGY


Two basic types of epidemiology are often applied in cancer. These include descriptive epidemiology and analytic epidemiology.





Descriptive Epidemiology


Descriptive epidemiology provides information about the occurrence of disease in a population or its subgroups and trends in the frequency of disease over time. In particular, this entails incidence and mortality rates and survival data. Sources of data include death certificates, cancer registries, surveys, and population censuses (Jennings-Dozier & Foltz, 2002). Descriptive measures are useful for identifying populations and subgroups at high and low risk of disease and for monitoring time trends for specific diseases. They provide the leads for analytic studies designed to investigate factors responsible for such disease profiles. Several common descriptive epidemiologic terms are described.



Incidence.


Incidence refers to the number of new cases of disease that occur during a specified period of time in a defined population at risk for development of the disease (ACS, 2007). Incidence rates also provide information about the risk for development of a disease or condition just by virtue of being a member of a specified population. The ACS publishes projected incidence rates annually for common cancers in its annual Cancer Facts & Figures publication (ACS, 2007).


The table on page 5 illustrates that the most commonly diagnosed cancers in the United States for women are cancers of the breast, lung, colon, lymphoma, and melanoma. For men the most commonly diagnosed cancers are cancers of the prostate and lung, lymphoma, and melanoma. The ACS estimates that overall there will be about 1.44 million new cases of cancer in the United States in 2007 (Jemal et al., 2007).



Mortality Rates.


The table on page 5 also shows the projected number of deaths from cancer in the United States. The mortality rate is the number of persons who are estimated to die from a particular cancer during a particular time. The ACS (2007) estimates that approximately 559,650 Americans will die from cancer during 2007. This translates to about 1,500 deaths per day (Jemal et al., 2007). For men, those cancers associated with the highest mortality rates are cancers of the lung, prostate, and colon, and for women the cancers with the highest mortality rates are associated with cancers of the lung, breast, and colon. These four cancers account for half the total cancer deaths among men and women (ACS, 2007).


Many epidemiologists consider the incidence and mortality rates together when making public health decisions. For example, breast cancer affects one in eight women (178,480 new cases) and results in 40,460 deaths annually. It accounts for 26% of new cases of cancer in women and 15% of deaths annually. Compare this with the figures for ovarian cancer. Ovarian cancer affects approximately one in 66 women (22,430 new cases) and results in 15,280 deaths annually. Thus it accounts for 3% of new cases of cancer in women but 6% of deaths annually. Examination of these figures suggests that ovarian cancer is either diagnosed at a later stage on average than breast cancer, or treatment is less effective, or both.




Definitions of Terms Used in Cancer Epidemiology


Absolute risk: the occurrence of the cancer in the general population (either incidence or mortality rate)


Asymptomatic: the person being screened and the examiner are unaware of any signs or symptoms of cancer in the individual before the screening test was initiated


Attributable risk: the number of cases of cancer that could be prevented with the manipulation of known risk factors


Cancer screening test: a method or strategy used to detect a specific target cancer. It may be a single modality, but often is a combination of tests. Laboratory tests of blood or body fluids, imaging tests, physical examination, and invasive procedures are all sometimes used for screening tests.


Cost-effectiveness: a financial indicator that is achieved if the costs of the screening program are less than the costs in the unscreened group


Diagnostic tests: tests used in those with symptoms of cancer or abnormal screening tests. The purpose of diagnostic testing is to determine the cause of symptoms or abnormal screening test results.


Effectiveness: a measure determined by comparing the outcomes to determine whether the benefits outweigh the risks and harms and the actual costs of the benefits


False negative: a test result indicating that the tested person does not have a particular characteristic but the individual actually does (a negative mammogram in a woman with early breast cancer)


False positive: a test result indicating that the tested person does have a particular characteristic but the person actually does not (a very suspicious mammogram in a woman who does not have breast cancer)


Incidence: the number of cancers that develop in a population during a defined period of time, such as a year


Mortality rate: the number of persons who die of a particular cancer during a defined period of time, such as 1 year


Outcomes: health and economic results that occur related to screening. Outcomes may include the benefits, harms, and costs of screening or genetic testing and its incurred diagnostic evaluations. These may be short or long term in nature.


Prevalence: the number of cancers that exist in a defined population at a given point in time


Primary cancer prevention: measures to avoid carcinogen exposure, improve health practices, and, in some cases, the use of chemoprevention agents. Primary prevention may also include the use of prophylactic surgery to prevent or significantly reduce the development of a malignancy.


Relative risk: a statistical estimate that is a comparison of the likelihood of development of a cancer with a specific risk factor with a person who does not have the specific risk factor


Secondary cancer prevention: identification of persons at risk for development of malignancy and implementing appropriate screening recommendations. Terms often used interchangeably with secondary cancer prevention are early detection and cancer screening.


Sensitivity: ability of a screening test to detect individuals with the characteristic being screened for. It is calculated by dividing the total number of true positives by the total number of the population.


Target population: number of persons in a defined group who are capable of developing the disease and would be appropriate candidates for screening. Population may refer to the general population, or a specific group of people defined by geographic, physical, or social characteristics. For example, nurses who provide cancer genetics counseling need to assess whether a person is of Ashkenazi Jewish background. This special population of Jewish people is at higher risk for three specific mutations for hereditary breast cancer (Struewing et al., 1997).


Tertiary cancer prevention: efforts aimed at persons with a history of malignancy and includes monitoring for and preventing recurrence and screening for second primary cancers. In many cases, those who have had a diagnosis of cancer and who carry a mutation in a cancer susceptibility gene are at significantly higher risk for development of a second malignancy.


True negative: test result indicating that the tested person does not have the trait tested for and the person indeed does not (a woman has a negative mammogram and cancer does not develop in the next 12 to 24 months)


True positive: test result indicating that the tested person has the characteristic tested for and indeed the person does have it (a woman has a suspicious mammogram and a biopsy demonstrates the area is indeed a malignancy)


Validity: measure of how well a test measures what it is supposed to measure





Case-Fatality Rates.


Cancer case-fatality rates are often an important indicator of the effectiveness of a particular cancer detection or treatment method and the impact of the cancer in a defined population. Cancer case-fatality rates provide information about the likelihood of dying from cancer among those diagnosed with the disease (Jennings-Dozier & Foltz, 2002). Case-fatality rates are different than mortality rates in that the mortality rate represents an entire population at risk from dying from a cancer and includes those who do and do not have the cancer. Cancer case-fatality rates include only those who have the disease.



Risk Factor.


A risk factor is a trait or characteristic that is associated with a statistically significant and an increased likelihood of development of a disease (Mahon, 2002). It is important to note, however, that having a risk factor does not mean a person will develop a disease or malignancy, nor does the absence of a risk factor mean one will not develop a disease or malignancy.



Absolute Risk.


Absolute risk is a measure of the occurrence of cancer, either incidence (new cases) or mortality (deaths), in the general population. Absolute risk is helpful when a patient needs to understand what the chances are for all persons in a population having a particular disease. Absolute risk can be expressed either as the number of cases for a specified denominator (e.g., 131 cases of breast cancer per 100,000 women annually) or as a cumulative risk up to a specified age (e.g., one in eight women will develop breast cancer if they live to age 85 years) (ACS, 2007). Another way to express absolute risk is to discuss the average risk of having breast cancer at a certain age. For example, a woman’s risk for development of breast cancer may be 2% at age 50 years but at age 85 years it might be 13%. Risk estimates will be much different for a 50-year-old woman than for an 85-year-old woman because approximately 50% of the cases of breast cancer occur after the age of 65 years. This is illustrated in the table below.


Individuals need to understand that certain assumptions are made to reach an absolute risk figure for a particular cancer. For example, the one-in-eight figure describes the “average” risk of breast cancer in white American women and is calculated to take into consideration other causes of death over the life span. This figure overestimates breast cancer risk for some women with no risk factors and underestimates the risk for women with several risk factors. What this statistic actually means is that the average woman’s breast cancer risk is just 0.048% to age 40 years, 3.98% from 40 to 60 years, 3.65% from age 60 to 69 years, and 4.56% from age 70 years on. The 12.67% or one-in-eight risk is obtained by adding the risk in each age category (0.048 + 3.98 + 3.65 + 4.56 = 12.67%). When a woman who has an average risk reaches age 40 years without a diagnosis of breast cancer, she has passed through 0.048% of her risk, so her lifetime risk is 12.67% minus 0.48%, which equals 12.19%. When she reaches age 70 years without a diagnosis of breast cancer her risk is 12.67% − 0.048% − 3.98 − 3.65% = 4.52%. Time must always be considered for the absolute risk figure to be meaningful.



Relative Risk.


The term relative risk refers to a comparison of the incidence or deaths among those with a particular risk factor compared with those without the risk factor. By using relative risk factors, individuals can determine their risk factors and thus better understand their personal chances of development of a specific cancer compared with an individual without such risk factors. If the risk for a person with no known risk factors is 1.0%, the risk for those with known risk factors can be evaluated in relation to this figure.


This can be illustrated by considering several of the relative risk factors for breast cancer. A woman who has her first menstrual period before age 12 years has a 1.3% relative risk for development of breast cancer compared with a woman who has her first menstrual period after age 15 years (Singletary, 2003). For the woman with two first-degree relatives with premenopausal breast cancer, the relative risk is estimated to be 7.1% compared with the woman with no relatives with premenopausal breast cancer. This means she is 7.1 times more likely to develop breast cancer than is the woman without risk factors.



Only gold members can continue reading. Log In or Register to continue

Stay updated, free articles. Join our Telegram channel

Mar 1, 2017 | Posted by in NURSING | Comments Off on Cancer Epidemiology: Implications for Prevention, Early Detection, and Treatment

Full access? Get Clinical Tree

Get Clinical Tree app for offline access